|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
37,470,000 |
Market
Cap: |
316.25(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.28 - $13.99 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
4,872,988 |
Total Buy Value |
$0 |
$0 |
$0 |
$41,694,868 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
38,202 |
42,011 |
76,578 |
2,756,162 |
Total Sell Value |
$317,473 |
$344,745 |
$641,708 |
$21,052,273 |
Total People Sold |
4 |
4 |
4 |
9 |
Total Sell Transactions |
7 |
9 |
13 |
45 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ravina Bernard |
Chief Medical Officer |
|
2018-04-10 |
4 |
AS |
$18.38 |
$45,049 |
D/D |
(2,451) |
0 |
|
- |
|
Henderson Jane |
Sr. V.P. & CFO, Corp. Dev. |
|
2018-03-23 |
4 |
S |
$20.52 |
$229,824 |
D/D |
(11,200) |
0 |
|
- |
|
Henderson Jane |
Sr. V.P. & CFO, Corp. Dev. |
|
2018-03-23 |
4 |
OE |
$11.97 |
$134,064 |
D/D |
11,200 |
11,200 |
|
- |
|
Henderson Jane |
Sr. V.P. & CFO, Corp. Dev. |
|
2018-03-22 |
4 |
S |
$21.07 |
$419,293 |
D/D |
(19,900) |
0 |
|
- |
|
Henderson Jane |
Sr. V.P. & CFO, Corp. Dev. |
|
2018-03-22 |
4 |
OE |
$11.97 |
$238,203 |
D/D |
19,900 |
19,900 |
|
- |
|
Henderson Jane |
CFO & SVP, Corp. Dev. |
|
2018-03-19 |
4 |
S |
$21.76 |
$41,344 |
D/D |
(1,900) |
0 |
|
- |
|
Henderson Jane |
CFO & SVP, Corp. Dev. |
|
2018-03-19 |
4 |
OE |
$11.97 |
$22,743 |
D/D |
1,900 |
1,900 |
|
- |
|
Henderson Jane |
CFO & SVP, Corp. Dev. |
|
2018-03-16 |
4 |
S |
$22.15 |
$341,464 |
D/D |
(15,416) |
0 |
|
- |
|
Henderson Jane |
CFO & SVP, Corp. Dev. |
|
2018-03-16 |
4 |
OE |
$11.97 |
$184,530 |
D/D |
15,416 |
15,416 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2018-03-12 |
4 |
AS |
$25.16 |
$61,667 |
D/D |
(2,451) |
2,451 |
|
- |
|
Sah Dinah Ph.d. |
Chief Scientific Officer |
|
2018-02-27 |
4 |
AS |
$30.00 |
$468,690 |
D/D |
(15,623) |
138,688 |
|
- |
|
Sah Dinah Ph.d. |
Chief Scientific Officer |
|
2018-02-27 |
4 |
OE |
$7.27 |
$155,845 |
D/D |
15,623 |
154,311 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2018-02-12 |
4 |
AS |
$18.24 |
$44,706 |
D/D |
(2,451) |
4,902 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2018-01-10 |
4 |
AS |
$16.40 |
$59,532 |
D/D |
(3,630) |
7,353 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2017-12-11 |
4 |
AS |
$13.63 |
$74,829 |
D/D |
(5,490) |
10,983 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2017-11-10 |
4 |
AS |
$13.26 |
$72,797 |
D/D |
(5,490) |
16,473 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2017-10-10 |
4 |
AS |
$20.33 |
$223,223 |
D/D |
(10,980) |
21,963 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2017-09-11 |
4 |
AS |
$14.30 |
$157,014 |
D/D |
(10,980) |
32,943 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2017-09-05 |
4 |
AS |
$10.00 |
$54,900 |
D/D |
(5,490) |
17,157 |
|
- |
|
Ravina Bernard |
Chief Medical Officer |
|
2017-07-20 |
4 |
AS |
$10.00 |
$54,900 |
D/D |
(5,490) |
49,413 |
|
- |
|
Sah Dinah Ph.d. |
Chief Scientific OfficerOffice |
|
2017-06-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
138,688 |
|
- |
|
Ravina Bernard |
Chief Medical OfficerOfficer |
|
2017-06-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
117,647 |
|
- |
|
Levin Mark J |
Director |
|
2017-04-12 |
4 |
AS |
$0.00 |
$0 |
I/I |
(920,000) |
9,391,176 |
|
- |
|
Tepper Robert I |
10% Owner |
|
2017-04-12 |
4 |
AS |
$0.00 |
$0 |
D/D |
(920,000) |
9,391,176 |
|
- |
|
Levin Mark J |
Director |
|
2016-12-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(750,000) |
10,311,176 |
|
- |
|
162 Records found
|
|
Page 6 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|